Evaluation of the performance of new substitute tears in dry eye patients

Submission date	Recruitment status	Prospectively registered
28/07/2020	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
05/08/2020	Completed	[X] Results
Last Edited 20/06/2023	Condition category Eye Diseases	[] Individual participant data

Plain English summary of protocol

Background and study aims

Dry eye disease (when the eyes do not make enough tears, or the tears evaporate too quickly) is very common and affects millions of people around the world.

The aim of the study is verify the efficacy of a substitute tear containing 0.001% hydrocortisone to improve symptoms and inflammation in dry eye patients.

Who can participate?

Patients older than 18 years who have suffered from dry eye symptoms for at least 6 months

What does the study involve?

Participants will be randomly allocated to receive eye drops with or without 0.001% hydrocortisone. These will be used twice daily for one week to check for any problems. After the first week the drops will be used 4 times a day for 6 months. Participants will visit the clinic to be tested on day 7, 28, 56, 180.

What are the possible benefits and risks of participating?

The product used in the study has not demonstrated any side effects so far.

Where is the study run from?

Ocular Surface and Dry Eye Center, Sacco Hospital, Milan (Italy)

When is the study starting and how long is it expected to run for? March 2019 to April 2021

Who is funding the study? Investigator initiated and funded

Who is the main contact? Stefano Barabino, MD, PhD, at stefano.barabino@unimi.it

Contact information

Type(s)

Scientific

Contact name

Prof Stefano Barabino

ORCID ID

https://orcid.org/0000-0002-6317-8848

Contact details

Ospedale L. Sacco Via GB Grassi 74 Milan Italy 20157 +39-02-50319842 stefano.barabino@unimi.it

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

2019/ST/048

Study information

Scientific Title

Evaluation of the performance of a substitute tear containing hyaluronic acid and a low concentration of hydrocortisone to control ocular surface inflammation and symptoms in patients with dry eye disease

Study objectives

Substitute tear containing hyaluronic acid and low concentration of hydrocortisone improves symptoms and signs of dry eye disease

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 19/9/2019 Milan Area 1 Ethic Committee (Luigi Sacco hospital, via G.B. Grasi 74, Milan, Italy; +39 0239043518; comitato.etico@asst-fbf-sacco.it), ref: 39408/2019

Study design

Interventional double masked randomized study

Primary study design

Interventional

Secondary study design

Randomised parallel trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Dry eye disease

Interventions

Patients are randomized in study and control group using a pre-defined list. All patients will use topical steroid Fluorometholone twice daily and treatment (HA + 0.001% hydrocortisone) or control (HA alone) eye drops twice daily for one week. At the end of the first week, patients will keep using eye drops 4 times a day for 6 months

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

1. Fluorometholone 2. HA + 0.001% hydrocortisone

Primary outcome measure

Symptom improvement measured by SANDE score at day 7, 28, 56, 180

Secondary outcome measures

- 1. Corneal fluorescein staining, NEI scale, at day 7, 28, 56,180
- 2. Lissamine green conjunctival staining, NEI scale, at day 7, 28, 56, 180
- 3. Tear break-up time (BUT), seconds, at day 7, 28, 56, 180
- 4. Intraocular pressure (IOP), mmHg, at day 7, 28, 56, 180

Overall study start date

07/03/2019

Completion date

10/04/2021

Eligibility

Key inclusion criteria

- 1. Dry eye symptoms for at least 6 months, and one of the following signs:
- 1.1. Corneal fluorescein staining ≥3 (NEI National eye Institute grading scale)
- 1.2. Conjunctival lissamine green staining ≥ 3 (NEI National eye Institute grading scale)
- 1.3. T BUT (Tear Film Break up Time) ≤10 s

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

40

Total final enrolment

40

Key exclusion criteria

- 1. Patients changing systemic treatment during the study
- 2. Patients with other ocular surface diseases other than dry eye
- 3. Pregnancy
- 4. Diabetes
- 5. Ocular surgery in the previous 3 months

Date of first enrolment

10/06/2020

Date of final enrolment

10/04/2021

Locations

Countries of recruitment

Italy

Study participating centre Ospedale L. Sacco-University of Milan

Clinica Oculistica via GB Grassi 74 Milan Italy 20157

Sponsor information

Organisation

Luigi Sacco Hospital

Sponsor details

via GB Grassi 74 Milan Italy 20157 +39-02-50319842 cloculistica.sacco@unimi.it

Sponsor type

Hospital/treatment centre

Website

https://www.asst-fbf-sacco.it

ROR

https://ror.org/0025g8755

Funder(s)

Funder type

Other

Funder Name

investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

01/06/2021

Individual participant data (IPD) sharing plan

All data generated or analysed during this study will be included in the subsequent results publication

IPD sharing plan summary

Other

Study outputs

Output typeDetailsDate createdDate addedPeer reviewed?Patient-facing?Results article19/06/202320/06/2023YesNo